An investigation for investors in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares over potential securities laws violations by Sarepta Therapeutics, Inc. was announced.

San Diego, CA -- (SBWire) -- 01/18/2021 --Sarepta Therapeutics, Inc is under investigation over potential securities laws in connection with certain financial statements.

Investors who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Sarepta Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. On August 19, 2019, Sarepta Therapeutics, Inc. announced receipt of a Complete Response Letter ("CRL") from the U.S. Food & Drug Administration regarding the Company's New Drug Application seeking accelerated approval of golodirsen injection for the treatment of Duchenne muscular dystrophy. Sarepta disclosed that "[t]he CRL generally cites two concerns: the risk of infections related to intravenous infusion ports and renal toxicity seen in pre-clinical models of golodirsen and observed following administration of other antisense oligonucleotides."

On January 7, 2021, after market hours, Sarepta announced its gene therapy as a one-time treatment for the rare disorder Duchenne muscular dystrophy failed to show benefits compared with a placebo.

Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) declined from $174.30 per share on January 7, 2021, to as low as $82.25 per share on Januaey 8, 2021.

Those who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.